Humira and biosimilars — CareFirst (Caremark)

Initial criteria

• Member previously received biologic indicated for pyoderma gangrenosum OR inadequate response to corticosteroids or immunosuppressive therapy (cyclosporine, mycophenolate mofetil) OR intolerance/contraindication to corticosteroids and immunosuppressive therapy

Approval duration

12 months